At a radiotherapy conference in 2026, researchers from Kiel, Germany presented findings that could reshape how doctors treat breast cancer once it begins to spread: targeted radiation therapy, when combined with standard drugs, nearly doubled the time patients survived without their disease worsening.
The challenge with metastatic breast cancer is that once the disease spreads beyond the original tumor, treatment becomes harder and survival rates drop. But there's a window of opportunity when cancer spreads to just a few small spots in the body—a condition called oligometastatic breast cancer. Professor David Krug and his team wondered whether they could harness the precision of stereotactic body radiotherapy (SBRT), a technique that fires radiation beams from multiple angles around the body to converge on tumors with extraordinary accuracy, to treat those secondary growths before they multiply.
Between March 2021 and April 2024, the researchers enrolled 87 patients at 31 hospitals across Germany and Austria. Half received standard treatment—chemotherapy and hormone therapy designed to control the cancer systemically. The other half received that same standard treatment plus SBRT targeting each of their secondary tumors. The patients in the trial had between one and five small metastases, the ideal candidates for this approach.
The results were striking. Patients who received targeted radiotherapy lived for 36.2 months on average without their cancer progressing—essentially halving the risk of disease progression or death compared to the standard-treatment-only group, who survived progression-free for 20.6 months. That's a gain of more than 15 months, time that could mean more moments with family, more treatment options, more chance for quality life.
Equally important, Krug's team found no major impact on patients' quality of life from adding radiotherapy. When researchers assessed wellbeing using a standard questionnaire 12 weeks after treatment, both groups showed similar, minimal deterioration on a 0–100 scale. As Krug noted, the addition of radiotherapy meant "patients lived for longer without their cancer getting worse. It's also important that there was no major effect on the patient's quality of life."
The trial reveals something important about how patients think about their care, too. Recruitment proved slower than expected not because patients rejected the idea of radiotherapy, but because many wanted it so badly they refused to take the risk of being randomized to standard treatment alone. That enthusiasm from patients reflects growing confidence in precision radiation techniques—and a hunger for every tool available in the fight against cancer.
Still, the researchers caution that the trial was smaller than originally planned, limited by recruitment challenges. Many patients discovered to have metastatic disease already had too many tumors to qualify. Krug emphasizes that "further clinical trial results are needed to give a clearer picture" of how oligometastatic breast cancer responds to this combination approach. The next chapter—larger, more definitive trials—will determine whether this precision technique becomes standard practice worldwide.